As of 2026-08-16, the Intrinsic Value of Cardiol Therapeutics Inc (CRDL.TO) is -2.04 CAD. This CRDL.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.51 CAD, the upside of Cardiol Therapeutics Inc is -181.26%.
Based on its market price of 2.51 CAD and our intrinsic valuation, Cardiol Therapeutics Inc (CRDL.TO) is overvalued by 181.26%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.04 - -2.04 | -2.04 | -181.26% |
| P/E | (2.86) - (3.52) | (3.04) | -221.1% |
| DDM - Stable | (3.76) - (18.26) | (11.01) | -538.8% |
| DDM - Multi | (1.55) - (6.05) | (2.49) | -199.3% |
| Market Cap (mil) | 223.66 |
| Beta | 2.25 |
| Outstanding shares (mil) | 89.11 |
| Enterprise Value (mil) | 196.10 |
| Market risk premium | 5.10% |
| Cost of Equity | 8.80% |
| Cost of Debt | 5.00% |
| WACC | 8.80% |